Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

WIB_icon

Tandem CD19/CD20 CAR T Cells Produce Durable Antitumor Response in Relapsed/Refractory Non-Hodgkin Lymphoma

Infusions of tandem CD19- and CD20-targeting chimeric antigen receptor (CAR) T cells (TanCAR7) led to potent and durable antitumor responses in patients with relapsed/refractory...

Pediatric-Inspired Pegaspargase Regimen Shows Promise for Treatment of ALL/LBL

A pediatric-inspired treatment regimen incorporating pegaspargase timed to avoid overlapping toxicities was associated with manageable toxicity, high measurable residual disease (MRD) negativity rates, and...

Mogamulizumab Demonstrates Antitumor Activity in Adult T-Cell Leukemia/Lymphoma

Nearly two-thirds of patients with adult T-cell leukemia-lymphoma (ATLL) responded to treatment with mogamulizumab as a single agent or as part of a treatment...
WIB_icon

Sequential Pembrolizumab and Chemotherapy Results in Excellent Responses in Newly Diagnosed Classical Hodgkin Lymphoma

A brief course of pembrolizumab monotherapy followed by AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) was associated with reductions in metabolic tumor volume and prolonged...

Crizotinib Receives Priority Review for Pediatric ALCL

The FDA has granted priority review to a supplemental new drug application for crizotinib to treat pediatric patients with relapsed/refractory systemic anaplastic large cell...

Tafasitamab-cxix Receives Accelerated Approval for Relapsed/Refractory DLBCL

The FDA granted accelerated approval to tafasitamab-cxix in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma...
WIB_icon

Is Haploidentical Better Than Cord Blood Transplantation in Leukemia and Lymphoma?

Allogeneic hematopoietic cell transplantation with cord blood or haploidentical bone marrow extend access to transplantation for patients who lack a human leukocyte antigen (HLA)–matched...

Evaluating Selinexor in Patients With Relapsed/Refractory DLBCL

Oral selinexor demonstrated durable activity and a 28% response rate in patients with previously treated relapsed and refractory diffuse large B-cell lymphoma (DLBCL), according...
WIB_icon

Bispecific Immune Cell Engager AFM13 Plus Pembrolizumab Produces High Responses in Heavily Treated Hodgkin...

In a phase Ib study published in Blood, treatment with AFM13, a CD30/CD16A bispecific tetravalent innate immune cell engager, was safe and produced promising...

First CAR T-Cell Treatment Approved for Mantle Cell Lymphoma

The FDA granted accelerated approval to brexucabtagene autoleucel (formerly KTE-X19), a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with...
Advertisement

Current Issue

December 2020, Volume 6, Issue 15

This issue explores non-clinical career opportunities for doctors, hematologic concerns for transgender patients, and more.

Block title